title: Impact of statin therapy on late target lesion revascularization after sirolimus-eluting stent implantation (from the CREDO-Kyoto Registry Cohort-2).
abstract: Therapeutic strategies preventing late target lesion revascularization (TLR) after drug-eluting stent implantation have not been yet adequately investigated. In 13,087 consecutive patients undergoing first percutaneous coronary intervention in the CREDO-Kyoto Registry Cohort-2, we identified 10,221 patients who were discharged alive after implantation of sirolimus-eluting stents (SESs) only (SES stratum 5,029) or bare-metal stents (BMSs) only (BMS stratum 5,192). Impact of statin therapy at time of discharge from the index hospitalization on early (within the first year) and late (1 year to 4 years) TLR, was assessed in the SES stratum (statin group 2,735; nonstatin group 2,294) and in the BMS stratum (statin group 2,576; nonstatin group 2,616). Despite a significantly lower incidence of early TLR (7.8% vs 22.2%, p <0.0001), SES use compared to BMS use was associated with a significantly higher incidence of late TLR (7.7% vs 3.0%, p <0.0001). In the SES and BMS strata, the incidence of early TLR was similar regardless of statin use. In the SES stratum, the incidence of late TLR was significantly lower in the statin group than in the nonstatin group (6.1% vs 9.6%, p = 0.002), whereas no significant difference was found in the BMS stratum (2.6% vs 3.3%, p = 0.38). After adjusting confounders, risk for late TLR significantly favored statin use in the SES stratum (hazard ratio 0.73, 95% confidence interval 0.54 to 0.98, p = 0.04), whereas the risk decrease was not significant in the BMS stratum (hazard ratio 0.74, 95% confidence interval 0.46 to 1.20, p = 0.23). In conclusion, statin therapy at hospital discharge was associated with a significantly lower risk for late TLR after SES implantation.
authors.affiliation: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Natsuaki
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nakagawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Morimoto
authors.forename: Koh
authors.initials: K
authors.lastname: Ono
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shizuta
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Furukawa
authors.forename: Kazushige
authors.initials: K
authors.lastname: Kadota
authors.forename: Masashi
authors.initials: M
authors.lastname: Iwabuchi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kato
authors.forename: Satoru
authors.initials: S
authors.lastname: Suwa
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Inada
authors.forename: Osamu
authors.initials: O
authors.lastname: Doi
authors.forename: Akinori
authors.initials: A
authors.lastname: Takizawa
authors.forename: Masakiyo
authors.initials: M
authors.lastname: Nobuyoshi
authors.forename: Toru
authors.initials: T
authors.lastname: Kita
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kimura
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000494:pharmacology; D015994:Incidence; D008297:Male; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000601:surgery*; D009204:Myocardial Revascularization / Q000379:methods*; D012189:Retrospective Studies; D020123:Sirolimus / Q000494:pharmacology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus